National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 55 of 66
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00030498
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
NCT00027599
Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00029003
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
NCT00030381
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT00030693
Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States
NCT00340457
Fungicide Exposure Assessment Among Apple and Peach Farmers in the Argicultural Health Study
NCT00342394
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews
NCT00341900
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
NCT00339963
Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different Methods
NCT00339443
The Incidence of Breast and Other Cancers Among Female Flight Attendants
NCT00342407
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00023712
Molecular Epidemiology of Cutaneous Malignant Melanoma
NCT00341991
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00030368
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00030537
Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma
NCT00022555
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
NCT00028496
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
NCT00028535
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00026104
Bortezomib in Treating Children With Advanced Solid Tumors
NCT00021216
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
NCT00026221
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
NCT00026364
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
NCT00025363
Case-Control Study of Pesticides and Childhood Leukemia
NCT00342888
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT00026312
B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency
NCT00024934
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
NCT00023933
Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer
NCT00020631
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
NCT00026143
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00027872
Tenofovir Disoproxil Fumarate to Treat Pediatric HIV
NCT00024986
Biological Specimen Collection for Laboratory Methods Development and Training Purposes
NCT00025831
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
NCT00027703
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00026182
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
NCT00028782
BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00028561
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
NCT00026780
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
NCT00025246
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
NCT00025220
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00025467
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
NCT00030095
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
NCT00025506
Gefitinib in Treating Patients With Malignant Mesothelioma
NCT00025207
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
NCT00026091
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
NCT00025337
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
NCT00026169
Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)
NCT00023010
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
NCT00022971
Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer
NCT00340847
PS-341 in Treating Women With Metastatic Breast Cancer
NCT00025584
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.